{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T01:38:21Z","timestamp":1794965901217,"version":"4.9.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    SOLACE2 (ACTRN12618000686202) investigates whether 12-weeks of olaparib, or cyclophosphamide-olaparib priming, improves subsequent durvalumab-olaparib progression-free survival (PFS), and is superior to olaparib monotherapy without any priming, in platinum-sensitive recurrent ovarian cancer (n\u2009=\u2009114). We also evaluate the utility of CUP-CC assay, an immune signature of C-C chemokine receptor type 4 up-regulation, chemokines, and cytokines. Priming with olaparib, or cyclophosphamide-olaparib, followed by durvalumab-olaparib, are both associated with longer PFS compared to olaparib monotherapy, but do not reach the pre-specified primary endpoint of 36-week trial threshold (PFS36). PFS36 rates are 47.4% (95% CI, 31.0-62.1; olaparib priming then olaparib-durvalumab), 48.7% (32.5-63.2; olaparib-cyclophosphamide then olaparib-durvalumab) and 35.1% (20.4-50.3; olaparib monotherapy). PFS is significantly longer for the homologous recombination deficient (N\u2009=\u200971) as compared to the proficient (HRP) (N\u2009=\u200929) subgroups (Hazard Ratio (HR) 0.55, 0.35-0.87). CUP-CC+ subgroup (N\u2009=\u200958) has a significantly longer PFS (HR 0.31, 0.19-0.49) than CUP-CC- (N\u2009=\u200946). Future studies should investigate whether CUP-CC has the potential to personalize poly (ADP-ribose) polymerase inhibitor therapies for patients who are\n                    <jats:italic>BRCA<\/jats:italic>\n                    wild-type, including HRP patients.\n                  <\/jats:p>","DOI":"10.1038\/s41467-025-64130-6","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T12:54:43Z","timestamp":1762347283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Olaparib, durvalumab, and cyclophosphamide, and a prognostic blood signature in platinum-sensitive ovarian cancer: the randomized phase 2 SOLACE2 trial"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2955-9820","authenticated-orcid":false,"given":"Chee Khoon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Apriliana E. R.","family":"Kartikasari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5847-0277","authenticated-orcid":false,"given":"Nirashaa T.","family":"Bound","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8555-0161","authenticated-orcid":false,"given":"Katherine E.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3969-9846","authenticated-orcid":false,"given":"Kristy","family":"Shield-Artin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5704-0212","authenticated-orcid":false,"given":"Justin","family":"Bedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9972-9819","authenticated-orcid":false,"given":"Ksenija","family":"Nesic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Diamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel L.","family":"O\u2019Connell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutsa","family":"Madondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Momodou","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-0914","authenticated-orcid":false,"given":"Claire","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyril","family":"Deceneux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia","family":"Goodchild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Jarratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-3214-4613","authenticated-orcid":false,"given":"Emily","family":"Cassar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6359-4956","authenticated-orcid":false,"given":"Hina","family":"Amer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3540-8607","authenticated-orcid":false,"given":"U. G. Imalki U.","family":"Kariyawasam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeh Chen","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janine","family":"Lombard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9748-1458","authenticated-orcid":false,"given":"Sally","family":"Baron-Hay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoland","family":"Antill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshan","family":"Selva-Nayagam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Beale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danka","family":"Zebic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1274-2575","authenticated-orcid":false,"given":"Sandy","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anneliese","family":"Linaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1102-8506","authenticated-orcid":false,"given":"Anthony T.","family":"Papenfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6624-4698","authenticated-orcid":false,"given":"Matthew J.","family":"Wakefield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8891-8873","authenticated-orcid":false,"given":"Cassandra J.","family":"Vandenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3090-795X","authenticated-orcid":false,"given":"Michael","family":"Friedlander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3689-5956","authenticated-orcid":false,"given":"Clare L.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6889-3667","authenticated-orcid":false,"given":"Magdalena","family":"Plebanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"64130_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA: A Cancer J. Clinicians 74, 12\u201349 (2024).","journal-title":"CA: A Cancer J. Clinicians"},{"key":"64130_CR2","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1002\/ijc.34002","volume":"151","author":"CJ Cabasag","year":"2022","unstructured":"Cabasag, C. J. et al. Ovarian cancer today and tomorrow: A global assessment by world region and Human Development Index using GLOBOCAN 2020. Int. J. Cancer 151, 1535\u20131541 (2022).","journal-title":"Int. J. Cancer"},{"key":"64130_CR3","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1093\/annonc\/mds203","volume":"23","author":"LC Hanker","year":"2012","unstructured":"Hanker, L. C. et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane\/platinum-based therapy. Ann. Oncol. 23, 2605\u20132612 (2012).","journal-title":"Ann. Oncol."},{"key":"64130_CR4","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","volume":"30","author":"C Aghajanian","year":"2012","unstructured":"Aghajanian, C. et al. OCEANS: a randomized, double-blind, placebo-controlled phase iii trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J. Clin. Oncol. 30, 2039\u20132045 (2012).","journal-title":"J. Clin. Oncol."},{"key":"64130_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","volume":"35","author":"BJ Monk","year":"2024","unstructured":"Monk, B. J. et al. Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial. Ann. Oncol. 35, 981\u2013992 (2024).","journal-title":"Ann. Oncol."},{"key":"64130_CR6","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.annonc.2023.05.005","volume":"34","author":"I Ray-Coquard","year":"2023","unstructured":"Ray-Coquard, I. et al. Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1\/ENGOT-ov25 trial. Ann. Oncol. 34, 681\u2013692 (2023).","journal-title":"Ann. Oncol."},{"key":"64130_CR7","doi-asserted-by":"publisher","first-page":"LBA5506","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA5506","volume":"41","author":"P Harter","year":"2023","unstructured":"Harter, P. et al. Durvalumab with paclitaxel\/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1\/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial. J. Clin. Oncol. 41, LBA5506\u2013LBA5506 (2023).","journal-title":"J. Clin. Oncol."},{"key":"64130_CR8","doi-asserted-by":"publisher","first-page":"3671","DOI":"10.1200\/JCO.21.00334","volume":"39","author":"J Hamanishi","year":"2021","unstructured":"Hamanishi, J. et al. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J. Clin. Oncol. 39, 3671\u20133681 (2021).","journal-title":"J. Clin. Oncol."},{"key":"64130_CR9","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","volume":"22","author":"E Pujade-Lauraine","year":"2021","unstructured":"Pujade-Lauraine, E. et al. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study. Lancet Oncol. 22, 1034\u20131046 (2021).","journal-title":"Lancet Oncol."},{"key":"64130_CR10","doi-asserted-by":"crossref","unstructured":"Cassar, E., Kartikasari, A. E. R. & Plebanski, M. Regulatory T Cells in ovarian carcinogenesis and future therapeutic opportunities. Cancers (Basel). 14, 5488 (2022).","DOI":"10.3390\/cancers14225488"},{"key":"64130_CR11","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ctrv.2015.11.005","volume":"42","author":"MT Madondo","year":"2016","unstructured":"Madondo, M. T., Quinn, M. & Plebanski, M. Low dose cyclophosphamide: Mechanisms of T cell modulation. Cancer Treat. Rev. 42, 3\u20139 (2016).","journal-title":"Cancer Treat. Rev."},{"key":"64130_CR12","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41416-018-0349-6","volume":"120","author":"CK Lee","year":"2019","unstructured":"Lee, C. K. et al. Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer. Br. J. Cancer 120, 279\u2013285 (2019).","journal-title":"Br. J. Cancer"},{"key":"64130_CR13","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1200\/JCO.2014.58.8848","volume":"33","author":"CL Scott","year":"2015","unstructured":"Scott, C. L., Swisher, E. M. & Kaufmann, S. H. Poly (ADP-Ribose) Polymerase Inhibitors: Recent Advances and Future Development. J. Clin. Oncol. 33, 1397\u20131406 (2015).","journal-title":"J. Clin. Oncol."},{"key":"64130_CR14","doi-asserted-by":"publisher","first-page":"4268","DOI":"10.1158\/1078-0432.CCR-20-0056","volume":"26","author":"EJ Lampert","year":"2020","unstructured":"Lampert, E. J. et al. Combination of PARP inhibitor Olaparib, and PD-L1 inhibitor durvalumab, in recurrent ovarian cancer: a proof-of-concept phase ii study. Clin. Cancer Res. 26, 4268\u20134279 (2020).","journal-title":"Clin. Cancer Res."},{"key":"64130_CR15","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-018-0188-5","volume":"119","author":"A Ghaffari","year":"2018","unstructured":"Ghaffari, A. et al. STING agonist therapy in combination with PD-1 immune checkpoint blockade enhances response to carboplatin chemotherapy in high-grade serous ovarian cancer. Br. J. Cancer 119, 440\u2013449 (2018).","journal-title":"Br. J. Cancer"},{"key":"64130_CR16","doi-asserted-by":"publisher","DOI":"10.1177\/1179554921996288","volume":"15","author":"Z Wu","year":"2021","unstructured":"Wu, Z. et al. The Synergistic Effect of PARP Inhibitors and Immune Checkpoint Inhibitors. Clin. Med Insights Oncol. 15, 1179554921996288 (2021).","journal-title":"Clin. Med Insights Oncol."},{"key":"64130_CR17","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41416-023-02311-0","volume":"129","author":"S Thavaneswaran","year":"2023","unstructured":"Thavaneswaran, S. et al. A signal-seeking Phase 2 study of olaparib and durvalumab in advanced solid cancers with homologous recombination repair gene alterations. Br. J. Cancer 129, 475\u2013485 (2023).","journal-title":"Br. J. Cancer"},{"key":"64130_CR18","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/nm1093","volume":"10","author":"TJ Curiel","year":"2004","unstructured":"Curiel, T. J. et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10, 942\u2013949 (2004).","journal-title":"Nat. Med."},{"key":"64130_CR19","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/bjc.2011.189","volume":"105","author":"MJM Gooden","year":"2011","unstructured":"Gooden, M. J. M., de Bock, G. H., Leffers, N., Daemen, T. & Nijman, H. W. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br. J. Cancer 105, 93\u2013103 (2011).","journal-title":"Br. J. Cancer"},{"key":"64130_CR20","doi-asserted-by":"crossref","unstructured":"Wilson, A. L. et al. DPP4 Inhibitor Sitagliptin Enhances Lymphocyte Recruitment and Prolongs Survival in a Syngeneic Ovarian Cancer Mouse Model. Cancers (Basel) 13, 487 (2021).","DOI":"10.3390\/cancers13030487"},{"key":"64130_CR21","doi-asserted-by":"crossref","unstructured":"Wang, Y. et al. IL-6 mediates platinum-induced enrichment of ovarian cancer stem cells. JCI Insight 3, e122360 (2018).","DOI":"10.1172\/jci.insight.122360"},{"key":"64130_CR22","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1715064","volume":"2020","author":"I Wertel","year":"2020","unstructured":"Wertel, I. et al. Prognostic and Clinical Value of Interleukin 6 and CD45+CD14+ Inflammatory Cells with PD-L1+\/PD-L2+ Expression in Patients with Different Manifestation of Ovarian Cancer. J. Immunol. Res. 2020, 1715064 (2020).","journal-title":"J. Immunol. Res."},{"key":"64130_CR23","doi-asserted-by":"publisher","first-page":"31593","DOI":"10.18632\/oncotarget.3415","volume":"6","author":"EA Stronach","year":"2015","unstructured":"Stronach, E. A. et al. The role of interleukin-8 (IL-8) and IL-8 receptors in platinum response in high grade serous ovarian carcinoma. Oncotarget 6, 31593\u201331603 (2015).","journal-title":"Oncotarget"},{"key":"64130_CR24","doi-asserted-by":"crossref","unstructured":"Adzibolosu, N. et al. Immunological modifications following chemotherapy are associated with delayed recurrence of ovarian cancer. Front. Immunol. 14, 1204148 (2023).","DOI":"10.3389\/fimmu.2023.1204148"},{"key":"64130_CR25","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1007\/s13277-015-3133-8","volume":"36","author":"I Wertel","year":"2015","unstructured":"Wertel, I. et al. Macrophage-derived chemokine CCL22 and regulatory T cells in ovarian cancer patients. Tumour Biol. 36, 4811\u20134817 (2015).","journal-title":"Tumour Biol."},{"key":"64130_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(16)30559-9","volume":"18","author":"EM Swisher","year":"2017","unstructured":"Swisher, E. M. et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. Lancet Oncol. 18, 75\u201387 (2017).","journal-title":"Lancet Oncol."},{"key":"64130_CR27","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","volume":"375","author":"MR Mirza","year":"2016","unstructured":"Mirza, M. R. et al. Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer. N. Engl. J. Med. 375, 2154\u20132164 (2016).","journal-title":"N. Engl. J. Med."},{"key":"64130_CR28","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","volume":"390","author":"RL Coleman","year":"2017","unstructured":"Coleman, R. L. et al. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390, 1949\u20131961 (2017).","journal-title":"Lancet"},{"key":"64130_CR29","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(16)30376-X","volume":"17","author":"JA Ledermann","year":"2016","unstructured":"Ledermann, J. A. et al. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial. Lancet Oncol. 17, 1579\u20131589 (2016).","journal-title":"Lancet Oncol."},{"key":"64130_CR30","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a <em>BRCA1\/2<\/em> mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274\u20131284 (2017).","journal-title":"Lancet Oncol."},{"key":"64130_CR31","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1002\/cncr.33517","volume":"127","author":"CK Lee","year":"2021","unstructured":"Lee, C. K. et al. Molecular and clinical predictors of improvement in progression-free survival with maintenance PARP inhibitor therapy in women with platinum-sensitive, recurrent ovarian cancer: A meta-analysis. Cancer 127, 2432\u20132441 (2021).","journal-title":"Cancer"},{"key":"64130_CR32","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1158\/1078-0432.CCR-23-2249","volume":"30","author":"Y Drew","year":"2024","unstructured":"Drew, Y. et al. Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Na\u00efve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study. Clin. Cancer Res. 30, 50\u201362 (2024).","journal-title":"Clin. Cancer Res."},{"key":"64130_CR33","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1002\/eji.201040443","volume":"40","author":"SP Singh","year":"2010","unstructured":"Singh, S. P. et al. Changes in histone acetylation and methylation that are important for persistent but not transient expression of CCR4 in human CD4+ T cells. Eur. J. Immunol. 40, 3183\u20133197 (2010).","journal-title":"Eur. J. Immunol."},{"key":"64130_CR34","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood.2022015752","volume":"142","author":"D Frank","year":"2023","unstructured":"Frank, D. et al. Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy. Blood 142, 2175\u20132191 (2023).","journal-title":"Blood"},{"key":"64130_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22582-6","volume":"12","author":"EM Swisher","year":"2021","unstructured":"Swisher, E. M. et al. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). Nat. Commun. 12, 2487 (2021).","journal-title":"Nat. Commun."},{"key":"64130_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-05564-z","volume":"9","author":"O Kondrashova","year":"2018","unstructured":"Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. Nat. Commun. 9, 3970 (2018).","journal-title":"Nat. Commun."},{"key":"64130_CR37","first-page":"1375","volume":"69","author":"R Simon","year":"1985","unstructured":"Simon, R., Wittes, R. E. & Ellenberg, S. S. Randomized phase II clinical trials. Cancer Treat. Rep. 69, 1375\u20131381 (1985).","journal-title":"Cancer Treat. Rep."},{"key":"64130_CR38","doi-asserted-by":"crossref","unstructured":"Bedo J., Di Stefano L., Papenfuss A. T. Unifying package managers, workflow engines, and containers: Computational reproducibility with BioNix. Gigascience 9, giaa121 (2020).","DOI":"10.1093\/gigascience\/giaa121"},{"key":"64130_CR39","doi-asserted-by":"publisher","first-page":"D916","DOI":"10.1093\/nar\/gkaa1087","volume":"49","author":"A Frankish","year":"2021","unstructured":"Frankish, A. et al. Gencode 2021. Nucleic Acids Res 49, D916\u2013D923 (2021).","journal-title":"Nucleic Acids Res"},{"key":"64130_CR40","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-022-02831-7","volume":"23","author":"K Sahlin","year":"2022","unstructured":"Sahlin, K. Strobealign: flexible seed size enables ultra-fast and accurate read alignment. Genome Biol. 23, 260 (2022).","journal-title":"Genome Biol."},{"key":"64130_CR41","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/s41587-021-00861-3","volume":"39","author":"DP Cooke","year":"2021","unstructured":"Cooke, D. P., Wedge, D. C. & Lunter, G. A unified haplotype-based method for accurate and comprehensive variant calling. Nat. Biotechnol. 39, 885\u2013892 (2021).","journal-title":"Nat. Biotechnol."},{"key":"64130_CR42","doi-asserted-by":"publisher","first-page":"D891","DOI":"10.1093\/nar\/gkad1049","volume":"52","author":"PW Harrison","year":"2024","unstructured":"Harrison, P. W. et al. Ensembl 2024. Nucleic Acids Res 52, D891\u2013D899 (2024).","journal-title":"Nucleic Acids Res"},{"key":"64130_CR43","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/humu.21517","volume":"32","author":"X Liu","year":"2011","unstructured":"Liu, X., Jian, X. & Boerwinkle, E. dbNSFP: a lightweight database of human nonsynonymous SNPs and their functional predictions. Hum. Mutat. 32, 894\u2013899 (2011).","journal-title":"Hum. Mutat."},{"key":"64130_CR44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.3389\/fgene.2012.00035","volume":"3","author":"P Cingolani","year":"2012","unstructured":"Cingolani, P. et al. Using Drosophila melanogaster as a Model for Genotoxic Chemical Mutational Studies with a New Program, SnpSift. Front Genet 3, 35 (2012).","journal-title":"Front Genet"},{"key":"64130_CR45","doi-asserted-by":"publisher","first-page":"e131","DOI":"10.1093\/nar\/gkw520","volume":"44","author":"R Shen","year":"2016","unstructured":"Shen, R. & Seshan, V. E. FACETS: allele-specific copy number and clonal heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res 44, e131 (2016).","journal-title":"Nucleic Acids Res"},{"key":"64130_CR46","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-015-0033-4","volume":"3","author":"AM Marquard","year":"2015","unstructured":"Marquard, A. M. et al. Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs. Biomark. Res. 3, 9 (2015).","journal-title":"Biomark. Res."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64130-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64130-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:07:22Z","timestamp":1762351642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-64130-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,5]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["64130"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-64130-6","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,5]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"CKL reports grants from Roche, Amgen, AstraZeneca and Merck KGaA, honoraria from AstraZeneca, Amgen, Janssen, GSK, Boehringer Ingelheim, MSD, Roche, Gilead, Novartis and Glenmark and meeting attendance support from AstraZeneca and Janssen. KEF reports honoraria from Janssen and Gilead, and meeting attendance support from BMS, Merck\/MSD, Gilead, and Pfizer. KN reports support for the present manuscript with an AACR-AstraZeneca Ovarian Cancer Research Fellowship, and support from the Stafford Fox Medical Research Foundation. MM reports a US patent, and AstraZeneca stock as an employee incentive. YCL reports institutional grants form BeiGene, honoraria from AstraZeneca and Eisai, and participation in an advisory board with AstraZeneca and GSK. JL reports honoraria from AstraZeneca, Eisai, Gilead, Novartis and GSK, meeting attendance support from GSK and Novartis, participation in an advisory board with AstraZeneca, and a leadership role as chair of the ANZGOG uterine tumor working group. SB-H reports honoraria from AstraZeneca, Gilead, GSK, Novartis, MSD and Eisai, meeting attendance support from Novartis, and reports a leadership role as a member of the ANZGOG ovarian cancer tumor working group. YA reports consulting fees from Eisai, GSK, AstraZeneca, Pfizer, MSD and Daiichi Sankyo, honoraria from GSK, AstraZeneca, MSD, Eisai and IQVIA, meeting attendance support from MSD, participation in and advisory board with GSK, Eisai, AstraZeneca, MSD and Pfizer, and a leadership role through participation on the ANZGOG Research Advisory Committee. CS reports honoraria from AstraZeneca, Gilead, GSK, Eli Lilly, Novartis, MSD and Eisai, participation in and advisory board with AstraZeneca, and a leadership role as a member of ANZGOG ovarian cancer working group. SS-N reports honoraria from AstraZeneca, MSD and Eisai, meeting attendance support from MSD and a leadership role on the South Australian Health Cancer Drug Committee. PB reported participation in an advisory board with GSK and AstraZeneca. DZ reports honoraria from Merck and Bayer. MAQ reports participation in an advisory board with GSK. ATP reports support for the current manuscript through and NHMRC investigator grant and a leadership role as past president of the Australian Bioinformatics and Computational Biology Society Inc. CV reports support for the current manuscript with support from the Stafford Fox Medical Research Foundation and from Victorian Medical Research Acceleration Fund, institutional grants from AstraZeneca, Boehringer Ingelheim, IDEAYA Biosciences and Eisai and the recipient of royalties from Venetoclax. MF reports investigator-initiated grant support for the study from AstraZeneca, consulting fees from AstraZeneca, Novartis, GSK, Incyclix, AbbVie and BioNTech, honoraria from AstraZeneca, GSK, MSD and Limbic, participation in an advisory board from AGITG IDSMB, Endo-3 trial and Domenica trial, and institutional grants from AstraZeneca, BeiGene and Novartis. CLS reports support for the current manuscript through an investigator led grant from AstraZeneca, an NHMRC investigator grant, support from the Stafford Fox Research Foundation, the OASIS philanthropic research grant from ANZGOG, and the Victorian Medical Research Acceleration Fund, research grants from AstraZeneca, Eisai, BeiGene, Sierra Oncology, Boehringer Ingelheim and IDEAYA, royalties from Navitoclax, Genentech, Abbott, and Walter and Eliza Hall Institute of Medical Research, meeting attendance support from AstraZeneca, advisory board participation with AstraZeneca, Eisai, Sierra Oncology, MSD and Takeda, a leadership role as GCIC director, chair of the board of the international rare cancer initiative, and chair of the board of ANZGOG, and drug provision as part of a research agreement from AstraZeneca, Clovis Oncology, Eisai, BeiGene, Sierra Oncology, Boehringer Ingelheim and Ideaya.MP reports support for the current manuscript through AstraZeneca clinical trial funding support, RMIT and WEHI translational research funding, and ANZGOG translational research funding, and a patent provisionally lodged on blood biomarkers to identify PARPi responders. All other authors (A.J., A.L., A.E.R.K., N.T.B., C.Da, C.De, E.C., G.G., H.A., U.G.K., J.B., K.D., K.S.A., M.C., M.J.W., R.L.O.C., and S.S.) declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9756"}}